5 results
Search Results
2. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.
- Author
-
Jones, Nicholas R., Roalfe, Andrea K., Adoki, Ibiye, Hobbs, F.D. Richard, and Taylor, Clare J.
- Subjects
META-analysis ,HEART failure patients ,MEDICAL protocols ,VENTRICULAR ejection fraction ,HEART failure treatment ,HEART ventricle diseases ,AGE factors in disease ,CHRONIC diseases ,COMPARATIVE studies ,HEALTH services accessibility ,LEFT heart ventricle ,HEART failure ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,SURVIVAL analysis (Biometry) ,COMORBIDITY ,EVALUATION research ,DISEASE progression ,STROKE volume (Cardiac output) - Abstract
Aim: To provide reliable survival estimates for people with chronic heart failure and explain variation in survival by key factors including age at diagnosis, left ventricular ejection fraction, decade of diagnosis, and study setting.Methods and Results: We searched in relevant databases from inception to August 2018 for non-interventional studies reporting survival rates for patients with chronic or stable heart failure in any ambulatory setting. Across the 60 included studies, there was survival data for 1.5 million people with heart failure. In our random effects meta-analyses the pooled survival rates at 1 month, 1, 2, 5 and 10 years were 95.7% (95% confidence interval 94.3-96.9), 86.5% (85.4-87.6), 72.6% (67.0-76.6), 56.7% (54.0-59.4) and 34.9% (24.0-46.8), respectively. The 5-year survival rates improved between 1970-1979 and 2000-2009 across healthcare settings, from 29.1% (25.5-32.7) to 59.7% (54.7-64.6). Increasing age at diagnosis was significantly associated with a reduced survival time. Mortality was lowest in studies conducted in secondary care, where there were higher reported prescribing rates of key heart failure medications. There was significant heterogeneity among the included studies in terms of heart failure diagnostic criteria, participant co-morbidities, and treatment rates.Conclusion: These results can inform health policy and individual patient advanced care planning. Mortality associated with chronic heart failure remains high despite steady improvements in survival. There remains significant scope to improve prognosis through greater implementation of evidence-based treatments. Further research exploring the barriers and facilitators to treatment is recommended. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
3. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
- Author
-
Canepa, Marco, Straburzynska‐Migaj, Ewa, Drozdz, Jaroslaw, Fernandez‐Vivancos, Carla, Pinilla, Jose Manuel Garcia, Nyolczas, Noemi, Temporelli, Pier Luigi, Mebazaa, Alexandre, Lainscak, Mitja, Laroche, Cécile, Maggioni, Aldo Pietro, Piepoli, Massimo F., Coats, Andrew J. S., Ferrari, Roberto, Tavazzi, Luigi, on behalf of the ESC‐HFA Heart Failure Long‐Term Registry Investigators, Straburzynska-Migaj, Ewa, Fernandez-Vivancos, Carla, and ESC-HFA Heart Failure Long-Term Registry Investigators
- Subjects
HEART failure ,OBSTRUCTIVE lung disease diagnosis ,CARDIOLOGY ,DISEASE prevalence ,ACE inhibitors ,PROGNOSIS ,ADRENERGIC beta blockers ,ALDOSTERONE antagonists ,COMPARATIVE studies ,HOSPITAL care ,LONGITUDINAL method ,OBSTRUCTIVE lung diseases ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL societies ,RESEARCH ,TIME ,COMORBIDITY ,EVALUATION research ,ACQUISITION of data ,THERAPEUTICS - Abstract
Aims: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.Methods and Results: Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.Conclusions: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM.
- Author
-
Sliwa, Karen, Mebazaa, Alexandre, Hilfiker‐Kleiner, Denise, Petrie, Mark C., Maggioni, Aldo P., Laroche, Cecile, Regitz‐Zagrosek, Vera, Schaufelberger, Maria, Tavazzi, Luigi, van der Meer, Peter, Roos‐Hesselink, Jolien W., Seferovic, Petar, van Spandonck‐Zwarts, Karin, Mbakwem, Amam, Böhm, Michael, Mouquet, Frederic, Pieske, Burkert, Hall, Roger, Ponikowski, Piotre, and Bauersachs, Johann
- Subjects
PERIPARTUM cardiomyopathy ,CARDIOMYOPATHIES ,HEART failure ,ADRENERGIC beta blockers ,THERAPEUTIC embolization ,PATIENTS ,TREATMENT of cardiomyopathies ,CARDIOVASCULAR agents ,MEDICAL care cost statistics ,CHILDBIRTH ,CARDIOVASCULAR diseases in pregnancy ,COMPARATIVE studies ,DEMOGRAPHY ,ETHNIC groups ,RESEARCH methodology ,MEDICAL cooperation ,PUERPERAL disorders ,RESEARCH ,DISEASE management ,COMORBIDITY ,SOCIOECONOMIC factors ,EVALUATION research ,ACQUISITION of data ,DISEASE complications ,DIAGNOSIS ,THERAPEUTICS - Abstract
Aims: The purpose of this study is to describe disease presentation, co-morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy (PPCM) living in countries belonging to the European Society of Cardiology (ESC) vs. non-ESC countries.Methods and Results: Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry. There were marked differences in socio-demographic parameters such as Human Development Index, GINI index on inequality, and Health Expenditure in PPCM patients from ESC vs. non-ESC countries (P < 0.001 each). Ethnicity was Caucasian (34%), Black African (25.8%), Asian (21.8%), and Middle Eastern backgrounds (16.4%). Despite the huge disparities in socio-demographic factors and ethnic backgrounds, baseline characteristics are remarkably similar. Drug therapy initiated post-partum included ACE inhibitors/ARBs and mineralocorticoid receptor antagonists with identical frequencies in ESC vs. non-ESC countries. However, in non-ESC countries, there was significantly less use of beta-blockers (70.3% vs. 91.9%) and ivabradine (1.4% vs. 17.1%), but more use of diuretics (91.3% vs. 68.8%), digoxin (37.0% vs. 18.0%), and bromocriptine (32.6% vs. 7.1%) (P < 0.001). More patients in non-ESC vs. ESC countries continued to have symptomatic heart failure after 1 month (92.3% vs. 81.3%, P < 0.001). Venous thrombo-embolic events, arterial embolizations, and cerebrovascular accidents were documented in 28 of 411 patients (6.8%). Neonatal death rate was 3.1%.Conclusion: PPCM occurs in women from different ethnic backgrounds globally. Despite marked differences in socio-economic background, mode of presentation was largely similar. Embolic events and persistent heart failure were common within 1 month post-diagnosis and required intensive, multidisciplinary management. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Chronic Disease Management Programmes: an adequate response to patients' needs?
- Author
-
Rijken, Mieke, Bekkema, Nienke, Boeckxstaens, Pauline, Schellevis, François G., De Maeseneer, Jan M., and Groenewegen, Peter P.
- Subjects
DISEASE management ,RESEARCH ,ANALYSIS of variance ,ATTITUDE (Psychology) ,DECISION making ,DIABETES ,EXPERTISE ,HEALTH care teams ,LIFE skills ,OBSTRUCTIVE lung diseases ,RESEARCH methodology ,MEDICAL needs assessment ,MEDICAL cooperation ,MEDICAL personnel ,PATIENTS ,CULTURAL pluralism ,REHABILITATION ,RESEARCH funding ,HEALTH self-care ,SOCIAL participation ,COMORBIDITY ,SOCIAL services case management ,CROSS-sectional method ,DESCRIPTIVE statistics - Abstract
Background Inspired by American examples, several European countries are now developing disease management programmes (DMPs) to improve the quality of care for patients with chronic diseases. Recently, questions have been raised whether the disease management approach is appropriate to respond to patient-defined needs. Objective In this article we consider the responsiveness of current European DMPs to patients' needs defined in terms of multimorbidity, functional and participation problems, and self-management. Method Information about existing DMPs was derived from a survey among country-experts. In addition, we made use of international scientific literature. Results Most European DMPs do not have a solid answer yet to the problem of multimorbidity. Methods of linking DMPs, building extra modules to deal with the most prevalent comorbidities and integration of case management principles are introduced. Rehabilitation, psychosocial and reintegration support are not included in all DMPs, and the involvement of the social environment of the patient is uncommon. Interventions tailored to the needs of specific social or cultural patient groups are mostly not available. Few DMPs provide access to individualized patient information to strengthen self-management, including active engagement in decision making. Conclusion To further improve the responsiveness of DMPs to patients' needs, we suggest to monitor 'patient relevant outcomes' that might be based on the ICF-model. To address the needs of patients with multimorbidity, we propose a generic comprehensive model, embedded in primary care. A goal-oriented approach provides the opportunity to prioritize goals that really matter to patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.